Artículo
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, Alcira Mercedes; Russo, Sofia; Girotti, Maria Romina
; Rabinovich, Gabriel Adrián
; Hill, Marcelo
Fecha de publicación:
03/2020
Editorial:
Wiley Blackwell Publishing, Inc
Revista:
Clinical and Experimental Immunology
ISSN:
0009-9104
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Immune checkpoint blockers improve the overall survival of a limitednumber of patients among different cancers. Identifying pathways thatinfluence the immunological and clinical response to treatment is criticalto improve the therapeutic efficacy and predict clinical responses. Recently,a key role has been assigned to innate immune mechanisms in checkpointblockade-driven anti-tumor responses. However, inflammatory pathwayscan both improve and impair anti-tumor immunity. In this review, wediscuss how different inflammatory pathways, particularly inflammasomeactivation, can influence the clinical outcome of immune checkpoint blockers.Inflammasome activation may reinforce anti-tumor immunity by boostingCD8+ T cell priming as well as by enhancing T helper type 17 (Th17)responses. In particular, we focus on the modulation of the cation channeltransmembrane protein 176B (TMEM176B) and the ectonucleotidase CD39as potential targets to unleash inflammasome activation leading to reinforcedanti-tumor immunity and improved efficacy of immune checkpointblockers. Future studies should be aimed at investigating the mechanismsand cell subsets involved in inflammasome-driven anti-tumor responses.
Palabras clave:
INFLAMMOSOME
,
IMMUNE CHECKPOINT BLOCKERS
,
TMEM176B
,
CANCER IMMUNOTHERAPY
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Segovia, Alcira Mercedes; Russo, Sofia; Girotti, Maria Romina; Rabinovich, Gabriel Adrián; Hill, Marcelo; Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 200; 2; 3-2020; 155-162
Compartir